ERBB2 and breast cancer: To summarize, our data suggest that molecular subclassification of HER2-positive breast-cancer patients and the development of a combination therapy targeting the Hippo pathway effectors might significantly counteract trastuzumab resistance and improve therapeutic outcomes in HER2-positive breast-cancer patients.